Mylan announces FDA approval for Qualaquin generic Mylan announced that it has received final approval from the FDA for its Abbreviated New Drug Application for Quinine Sulfate Capsules. This product is the generic version of Mutual Pharmaceutical's Qualaquin Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria.
Mylan November calls active on takeover speculation Mylan November 55 & 57.5 calls are active on total call volume of 7,100 contracts (200 puts) on takeover speculation. November call option implied volatility is at 36, December is at 34; compared to its 26-week average of 32 according to Track Data. Active call volume suggests traders taking positions for upside price movement.